The IvyGene Liver Test is beneficial for patients diagnosed with cirrhosis, hepatitis, NAFLD, diabetes, as well as other at-risk liver cancer conditions. Our test is a highly specific tool that can confirm the presence of liver cancer as early as stage 1.
Validated for multiple cancer types, the IvyGeneCORE test provides a quantitative score that, if elevated, may confirm the presence of cancer as early as stage 1. IvyGeneCORE has been validated for breast, colon, liver, and lung cancers.
AI and Next-Generation Sequencing identified gene targets that have higher methylation levels when cancer is present. By analyzing the methylation ratios at those specific gene targets in whole blood, the IvyGene Technology may confirm the presence of multiple cancers, as early as stage 1.
Utilizing AI and cutting-edge technology, the IvyGene Platform acts as a highly accurate biomarker to confirm multiple cancers early. Unlike many biomarkers, the IvyGene tests combine high sensitivity and specificity through a simple blood draw.